bioihbjkbjnl/mcl2 huggingface dataset:
Canadian CP Registry - Registre Canadien de la Paralysie Cérébrale
Condition: Cerebral Palsy
MeSH terms: Cerebral Palsy
Study type: Observational [Patient Registry]

Summary: 
      The Canadian Cerebral Palsy (CP) Registry is a confidential, nation-wide collection of
      medical and social information about children with cerebral palsy. The Registry was first
      implemented in 2003 in 6 administrative regions of Quebec and was later extended to
      paediatric centres in Newfoundland, Nova Scotia, Ontario, Alberta, and British Columbia. Over
      1850 children living with Cerebral Palsy have been registered so far. The Registry is the
      first national registry for cerebral palsy in North America.
    

Detailed description: 
      The Canadian Cerebral Palsy Registry is a multi-regional Canadian registry to identify
      potential risk factors related to pregnancy and interactions of the environment and genetics.
      The Registry provides researchers with the approximate number of children with cerebral palsy
      across Canada, and data in the Registry helps researchers explore reasons behind the causes
      of cerebral palsy, in addition to supporting studies which may lead to improvements in the
      overall care of children with CP.

      Cerebral palsy is the most common cause of physical disability in children in Canada and it
      is important that we gain a better understanding of its prevalence, risk factors and current
      clinical profile. The Canadian CP Registry provides valuable data from different Canadian
      regions which can be shared and analyzed so as to provide answers to these important
      questions. Specifically, the Registry serves to:

        -  Characterize the profile of children living with CP across the country

        -  Identify risk factors associated with CP

        -  Monitor the prevalence of CP across the country

        -  Provide a platform for subject recruitment for population-based research on CP
    

Observational model: Other
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Children living with a diagnosis of Cerebral Palsy in Canada.
      
Keywords: Cerebral Palsy; Canada; Registry
Fatty Acid Quality and Overweight (FO-study)
Condition: Weight Reduction and Insulin Sensitivity
MeSH terms: Overweight; Insulin Resistance; Weight Loss
Study type: Interventional

Summary: 
      The purpose of this study is to study the health effects of fatty acid quality in healthy,
      overweight individuals.
    


Intervention name(s): fatty acid quality and overweight
Intervention type(s): Dietary Supplement
Intervention description(s): Duration 12 weeks
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
PTH Comparison in Post Menopausal Women
Condition: Osteoporosis, Post-Menopausal
MeSH terms: Osteoporosis; Osteoporosis, Postmenopausal
Study type: Interventional
Phase: Phase 3

Summary: 
      Compare in postmenopausal women with established osteoporosis the effect of treatment with
      teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day
      subcutaneous on change in lumbar spine BMD.
    


Intervention name(s): teriparatide 20 micrograms/day subcutaneous; calcitonin 100 IU/day subcutaneous
Intervention type(s): Drug; Drug
Other intervention name(s): LY333334
Intervention MeSH terms: Teriparatide; Calcitonin; Salmon calcitonin; Calcitonin Gene-Related Peptide; Katacalcin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Analgesic Effect of Intra-articular Dexamethasone and Dexamethasone Added to Bupivacaine in Interscalene Brachial Plexus
Condition: Postoperative Pain
MeSH terms: Pain, Postoperative
Study type: Interventional
Phase: Phase 4

Summary: 
      the aim of this study was to investigate the analgesic efficacy of intra articular
      dexamethasone administration for arthroscopic shoulder surgery.
    

Detailed description: 
      shoulder surgery can be very painful and interscalene brachial plexus block is the gold
      standard in the management of acute pain after shoulder surgery. various local anaesthetic
      mixtures can be used to prolong local anaesthesia duration and epinephrine , opioids and
      dexamethasone are frequently used for this purpose. dexamethasone has also been found the
      prolong the duration of lidocaine axillary blocks and intravenous regional anaesthesia.
      intraarticular administration of medicines can be used for management of joint pain and
      opioids , local anaesthetics and dexamethasone are used for this purpose.In addition, there
      are no studies available to compare the different treatment methods used in clinical practice
      directly.
    

Intervention name(s): intraarticular dexamethasone; interscalene dexamethasone; serum phsyologic
Intervention type(s): Procedure; Procedure; Procedure
Intervention description(s): 2ml 8 mg dexamethasone administration for intraarticular; 2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine; interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
Other intervention name(s): dekort; dekort
Intervention MeSH terms: Dexamethasone; Dexamethasone acetate; BB 1101
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: dexamethasone; intraarticular injection; interscalene brachial plexus block
Multiple Symptoms in Cancer Patients a Cross Sectional Multi Center Study
Condition: Cancer
Study type: Observational

Summary: 
      This study will assess the occurrence of multiple symptoms in cancer patients of 5 German
      university hospitals. Primary goal of the study is to assess the prevalence of multiple
      symptoms and related symptom clusters (e.g. pain, fatigue and sleep disorder).
    

Detailed description: 
      Oncology patients experience a variety of symptoms as a result of disease and/or treatment.
      They often report co-occurrence of symptoms and functional impairments (Miaskowski 2007). To
      evaluate the prevalence of symptoms and identify symptom clusters and the influence of
      multiple symptoms on HRQoL, in and out patients of 5 German university hospitals currently
      undergoing cancer treatment are recruited. These patients are asked to complete the following
      instruments: Distress thermometer, health related quality of life questionnaire (EORTC QLQ
      C30) and MD. Anderson Symptom Inventory (MDASI (German version). In a subgroup of two
      participating hospitals patients, that score ≥ 3/10 (MDASI-subscales for pain, fatigue and/or
      sleep disorder) are asked to complete additional questionnaires: Brief Pain Inventory (BPI),
      Multidimensional Fatigue Inventory (MFI), Pittsburgh Sleep Quality Index (PSQI). The
      information gained will not be accessible for doctors in charge of the treatment and
      therefore not influence or alter the participants' treatment regimes.

      Primary endpoint of the study is to assess the prevalence of multiple symptoms and related
      symptom clusters (e.g. pain, fatigue and sleep disorder). Secondary endpoints are: symptom
      burden (intensity of symptoms and functional impairments), impact of symptom burden on HRQoL.

      The investigators aim to approve the value of standardized assessment of symptoms in clinical
      cancer care settings as an important precondition of early treatment and supportive care.
    

Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        in and out cancer patients of 5 German university hospitals currently undergoing cancer
        treatment
      
Keywords: Cancer; Symptom burden; Symptom cluster; Distress; Pain; Fatigue; Sleep disorder; HRQoL
Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)
Condition: Smile Lines
Study type: Interventional

Summary: 
      Filler study for smile lines in cheek folds
    


Intervention name(s): Restylane Silk
Intervention type(s): Device
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Efficacy of Radiofrequency Nucleoplasty and Targeted Disc Decompression in Lumbar Radiculopathy
Condition: Visual Analogue Pain Scale; Pain Measurement
MeSH terms: Radiculopathy
Study type: Observational

Summary: 
      The aim of this study is to compare early and long term efficacy of lumbar radiofrequency
      nucleoplasty and targeted disc decompression in patients with lumbar radiculopathy who failed
      previous conventional therapy. Medical records of 37 patients undergoing targeted disc
      decompression, 36 patients undergoing lumbar radiofrequency nucleoplasty were retrospectively
      examined.Visual Analogue Scale (VAS), Numerical Rating Scale (NRS), Functional Rating Index,
      Backache index, Oswestry Lumbar Back Pain Disability Index, Rolland-Morris Lumbar Back Pain
      Questionnaire scales were used before treatment and 1,6,12 months after the procedure. North
      American Spine Society Satisfaction Scale was used at 12th month after the procedure.
    


Intervention name(s): Group Decompression or Group Nucleoplasty
Intervention type(s): Procedure
Intervention description(s): Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA]
Other intervention name(s): ArthroCare Spine; SpineCATH®
Observational model: Case-Control
Time perspective: Retrospective
Sampling method: Probability Sample
Study population: 
        120 patients with lumbar radiculopathy undergoing nucleoplasty and targetted disc
        decompression in Algology Department of a University Hospital between 2010 and 2012 were
        retrospectively evaluated and complete data of only 73 patients were reached and they were
        included to the study
      
Keywords: Intervertebral disc disease; Radiculopathy; Chronic pain; Thermocoagulation
Bioavailability and Bioactivity of Red Wine Melatonin in Humans
Condition: Bioavailability
Study type: Interventional

Summary: 
      Melatonin (MLT) is a bioactive compound in red wine. The investigators will investigate the
      serum and salivary concentrations and antioxidant power of MLT after the intake of a glass of
      red wine. Twelve healthy volunteers were recruited to receive both 125 mL of red wine rich in
      MLT (10 ng mL-1) and without MLT (placebo), via a randomized, cross-over, and double-blind
      design. Serum and salivary MLT will be measured by liquid chromatography coupled to mass
      spectrometry (LC-MS) and enzyme-linked immunosorbent (ELISA), respectively. The ferric ion
      reducing antioxidant power (FRAP) will be analyzed.
    

Detailed description: 
      Melatonin (MLT) is a bioactive compound in red wine. No information is currently available on
      serum and salivary concentrations of MLT after drinking a glass of red wine, containing this
      indoleamine. Hence, in this study, the investigators will investigate the levels of MLT, in
      serum and saliva, soon after the intake of the MLT-rich red wine, and, correspondingly, they
      will verify the antioxidant power of the same biological fluids.

      This will be a randomized, crossover, double-blind, placebo-controlled study with two
      treatment arms. Twelve healthy volunteers will be recruited to receive both 125 mL of red
      wine rich in MLT (10 ng mL-1) and without MLT (placebo), via a randomized, cross-over, and
      double-blind design.

      Serum and salivary MLT will be measured by liquid chromatography coupled to mass spectrometry
      (LC-MS) and enzyme-linked immunosorbent (ELISA), respectively. The ferric ion reducing
      antioxidant power (FRAP) will be also analyzed.

      For serum analyses, samples will be collected at 0, 30, 60 and 90 min. For saliva analyses,
      samples will be collected at 0, 45 and 120 min.
    

Intervention name(s): Red wine with melatonin; Red wine without melatonin
Intervention type(s): Other; Other
Intervention description(s): Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1); Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
Intervention MeSH terms: Melatonin
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Keywords: Mediterranean diet; indoleamine; nutraceuticals; nutrition; oxidative stress
Calcium Metabolism in Mexican American Adolescents
Condition: Osteoporosis
MeSH terms: Osteoporosis
Study type: Interventional

Summary: 
      The purpose of this study is to identify calcium metabolism characteristics in Mexican
      American adolescents. The investigators predict that calcium requirements to maximize bone
      health in this population will be lower than for white youth but higher than their current
      intakes.
    

Detailed description: 
      Previously significant racial and sex differences in calcium retention and kinetics in
      adolescents has been found. Other minority groups have increased calcium absorption
      efficiency at low calcium intakes in contrast to white adolescents. Since Hispanics and
      specifically Mexican Americans will soon comprise an increasing proportion of our population.
      We propose to identify calcium metabolism characteristics in this group. We predict that
      calcium requirements to maximize bone health in this population will be lower than for white
      youth but higher than their current intakes.

      Thus the specific aims of this project include:

        -  to establish calcium requirements

        -  to establish the relationship between calcium intake and calcium absorption

        -  to identify the major physiological parameters(kidney, intestine, bone) that contribute
           to calcium retention in Mexican-American adolescents

      During this two-phase metabolic camp participants will consume either a higher calcium
      diet(1100-2300mg/d) or a lower calcium diet (600-1200mg/d) during the first 3-week phase and
      switch to the opposite regime during the second 3-week phase, with a 2-week washout period in
      between. Subjects will collect all excreta during both phases. Calcium absorption, height,
      weight, and bone density will evaluated throughout the 6-week period of the study.
    

Intervention name(s): Low Calcium Diet; High Calcium Diet
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.; The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
Intervention MeSH terms: Calcium, Dietary; Calcium
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Participant)
Primary purpose: Prevention
Keywords: calcium; healthy; Mexican-American adolescents; camp; girls; boys; bone
Phase 1A Study of the Safety of KSP/QRH Dimer
Condition: Healthy Adults
Study type: Interventional
Phase: Phase 1

Summary: 
      To evaluate the safety of orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G), a
      topically administered Li-Cor IRDye800CW labeled heptapeptide dimer (KSP/QRH Dimer) specific
      for human epithelial growth factor receptor 2 (HER2) and epidermal growth factor receptor
      (EGFR).
    

Detailed description: 
      This is a Phase IA study of the safety of an orally administered KSP-QRH-E3-IRDye800 (Peptide
      919288G) heptapeptide dimer for detection of neoplastic tissues in multiple areas of the
      gastrointestinal tract in humans. The investigators intend to enroll 25 evaluable subjects.
      The investigators expect to be able to enroll about 2-3 subjects per week, so the study
      should take about 2-3 months to complete.

      Interested, healthy subjects ages 25-100 who respond to recruitment advertising on
      UMHealthResearch.org and appear to be eligible based responses to inclusion/exclusion
      criteria questions will be scheduled for a study visit at MCRU. At the study visit, the
      subjects will review and sign the informed consent and eligibility will be confirmed. If
      eligible, subjects will provide a blood sample for clinical labs and a urine sample for
      urinalysis, as well as have an EKG. A negative urine pregnancy test for women of
      child-bearing potential is required to be eligible. Eligible subjects will consume the
      reconstituted KSP-QRH-E3-IRDye800 (Peptide 919288G). After 5 minutes, subjects will drink a
      minimum 4-8 ounces of tap water and vital signs will be taken. Subjects will remain in MCRU
      for observation for 30 minutes. Vital signs will be recorded after 30 minutes, and another
      EKG will be conducted. Subjects are required to return to MCRU to have a repeat blood draw
      for clinical labs and urinalysis within 24 to 48 hours after KSP-QRH-E3-IRDye800 (Peptide
      919288G) ingestion. The study team will conduct a verbal assessment for toxicity at this
      visit.
    

Intervention name(s): KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg; KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
Intervention type(s): Drug; Drug
Intervention description(s): The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).; The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Efficacy of Two Bolus Doses of Remifentanil on the Incidence of Coughing During Emergence of Anesthesia
Condition: Cough; Anesthesia
MeSH terms: Cough
Study type: Interventional

Summary: 
      This study is designed to compare the effects of two bolus doses of intravenous remifentanil
      given prior to the emergence of anesthesia:

        -  on the incidence of perioperative coughing

        -  on the time needed for the emergence of a desflurane-based anesthesia

        -  on the incidence of sore throat after extubation.

      The investigators hypothesis is that the use of a higher remifentanil bolus dose (0.5 mcg/kg)
      given prior to emergence of a desflurane-based anesthesia will reduce the incidence of
      perioperative coughing when compared to a lower dose of remifentanil (0.25 mcg/kg).
    

Detailed description: 
      Emergence is an important period of general anesthesia during which several problems can
      occur. Coughing, hypertension, tachycardia and agitation have been observed during emergence
      of general anesthesia.

      Most patients will cough during emergence. Different techniques and drugs have been studied
      to reduce coughing during emergence.

      There is some evidence supporting the administration of intravenous opioids prior to
      emergence of general anesthesia to reduce perioperative coughing, agitation and haemodynamic
      stimulation. However, depending on the type of opioids given, this may delay the emergence
      from anesthesia. The effect of a remifentanil infusion given in combination with isoflurane
      as the volatile agent has been shown to reduce the incidence of perioperative coughing
      without delaying the emergence of anesthesia. The effect of a small bolus of remifentanil
      given prior to emergence to prevent perioperative coughing has yet to be studied.

      Desflurane is a newer volatile agent allowing early recovery from anesthesia. This agent has
      led to earlier discharge and more rapid resumption of normal activities after surgery.
      However, an incidence of coughing around 70% has been reported after a desflurane-based
      anesthesia.

      This study will compare the effects of two bolus doses of remifentanil (0.25 mcg/kg to 0.5
      mcg/kg) when given prior to emergence to prevent perioperative coughing after a
      desflurane-based anesthesia.
    

Intervention name(s): Remifentanil; Remifentanil
Intervention type(s): Drug; Drug
Intervention description(s): Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia; Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
Intervention MeSH terms: Remifentanil
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Prevention